Journal Mobile Options
Table of Contents
Vol. 44, No. 4, 2000
Issue release date: November 2000
Eur Neurol 2000;44:236–241
(DOI:10.1159/000008243)

A 52-Week Study of the Efficacy of Rivastigmine in Patients with Mild to Moderately Severe Alzheimer’s Disease

Farlow M. · Anand R. · Messina Jr J. · Hartman R. · Veach J.
aDepartment of Neurology, Indiana University School of Medicine, Indianapolis, Ind., and bDepartments of Medical Affairs CNS and Statistics, Novartis Pharmaceuticals Corporation, East Hanover, N.J., USA

Individual Users: Register with Karger Login Information

Please create your User ID & Password





Contact Information











I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in

Abstract

The efficacy of a centrally active cholinesterase inhibitor, rivastigmine tartrate (ENA 713; Exelon®), in patients with mild to moderately severe Alzheimer’s disease was evaluated in a 26-week open-label extension of a 26-week, double-blind, placebo-controlled study. By 52 weeks, patients originally treated with 6–12 mg/day rivastigmine had significantly better cognitive function than patients originally treated with placebo.

Copyright © 2000 S. Karger AG, Basel



Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

References

  1. Leber P: Observations and suggestions on antidementia drug development. Alzheimer Dis Assoc Disord 1996;10(suppl 1):31–35.
  2. Leber P: Slowing the progression of Alzheimer disease: Methodologic issues. Alzheimer Dis Assoc Disord 1997;11(suppl 5):10–21.
  3. Enz A, Amstutz R, Boddeke H, Gmelin G, Malanowski J: Brain selective inhibition of acetylcholinesterase: A novel approach to therapy for Alzheimer’s disease. Prog Brain Res 1993; 98:431–438.
  4. Cutler NR, Polinsky RJ, Sramek JJ, Enz A, Jhee SS, Mancione L, Hourani J, Zolnouni P: Dose-dependent CSF acetylcholinesterase inhibition by SDZ ENA 713 in Alzheimer’s disease. Acta Neurol Scand 1998;97:244–250.
  5. Corey-Bloom J, Anand R, Veach J: A randomized trial evaluating the efficacy and safety of ENA 713 (rivastigmine tartrate), a new acetylcholinesterase inhibitor, in patients with mild to moderately severe Alzheimer’s disease. Int J Geriatr Psychopharmacol 1998;1:55–65.
  6. Rösler M, Anand R, Cicin-Sain A, Gauthier S, Agid Y, Dal-Bianco P, Stähelin HB, Hartman R, Gharabawi M, on behalf of the B303 Exelon Study Group: Efficacy and safety of rivastigmine in patients with Alzheimer’s disease: International randomised controlled trial. Br Med J 1999;318:633–640.
  7. Rosen WG, Mohs RC, Davis KL: A new rating scale for Alzheimer’s disease. Am J Psychiatry 1984;141:1356–1364.
  8. Davis KL, Mohs RC, Marin D, Purohit DP, Perl DP, Lantz M, Austin G, Haroutunian V: Cholinergic markers in elderly patients with early signs of Alzheimer disease. JAMA 1999;15:1401–1406.
  9. Kramer-Ginsberg E, Mohs RC, Aryan M, Lobel D, Silverman J, Davidson M, Davis KL: Clinical predictors of course of Alzheimer patients in a longitudinal study: A preliminary report. Psychopharmacol Bull 1988;24:458–462.
  10. Stern RG, Mohs RC, Davidson M, Schmeidler J, Silverman J, Kramer-Ginsberg E, Searcey T, Bierer L, Davis KL: A longitudinal study of Alzheimer’s disease: Measurement, rate, and predictors of cognitive deterioration. Am J Psychiatry 1994;151:390–396.


Pay-per-View Options
Direct payment This item at the regular price: USD 38.00
Payment from account With a Karger Pay-per-View account (down payment USD 150) you profit from a special rate for this and other single items.
This item at the discounted price: USD 26.50